Předchozí studie metabolického zdraví a stárnutí metforminu (ANTHEM)
Ovlivňuje citlivost na inzulín potenciál metforminu zpomalit stárnutí
Aging is the number one risk factor for the majority of chronic diseases. There are no pharmaceutical treatments to slow aging and prolong healthspan. The anti-diabetic drug metformin is considered a likely pharmaceutical candidate to slow aging. In this study, the investigators hypothesize that metformin treatment in subjects free of type 2 diabetes will improve insulin sensitivity and glucoregulation in insulin resistant individuals, but will decrease insulin sensitivity and glucoregulation in insulin sensitive subjects. Further, the investigators hypothesize that long-term metformin treatment will remodel mitochondria in a way that decreases mitochondrial function in subjects that are insulin sensitive, but improves mitochondrial function in subjects that are insulin resistant. The investigators will use a dual-site, 12- week drug intervention trial performed in a double-blind, placebo-controlled manner on 148 subjects recruited from two separate sites (Oklahoma Medical Research Foundation (OMRF) and University of Wisconsin-Madison (UWM)). After consent and initial subject screening for chronic disease, subjects will be stratified to insulin sensitive (IS) or insulin resistant (IR) groups. Over a 12- week intervention, half of each group will take metformin and half will take a placebo. Pre- and post--intervention, subjects will complete a series of procedures to assess insulin sensitivity, glucose regulation, and biomarkers of aging. The same subjects will provide a skeletal muscle biopsy pre-- and post-intervention to assess the change in mitochondrial function and mitochondrial remodeling with and without metformin treatment. By completion of this project, the investigators expect to provide evidence that helps further delineate who may benefit from metformin treatment to slow aging.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Although there is epidemiological support for health benefits of metformin in patient populations, it is not clear if these protective effects extend to those free of disease. Therefore, there is a need to perform human studies determining which subjects free of chronic disease benefit from metformin treatment. Retrospective analysis of a randomized, double-blinded clinical trial in our lab revealed that subjects who were insulin sensitive had no effect or negative effects on insulin sensitivity when taking metformin during an exercise training program. These data suggest that in some subjects, metformin has detrimental metabolic outcomes that could accelerate aging. There are data both in support of and refuting that metformin inhibits mitochondrial complex I action and/or mitochondrial remodeling. The overall objective of this trial is to determine if subjects currently free of disease benefit from metformin treatment. There are two critical questions that remain unanswered in human subjects: 1) does antecedent metabolic health influence responses to metformin, and 2) does long-term treatment with metformin lead to mitochondrial remodeling and changes in function. To better understand the translational potential of a clinically relevant dose of metformin for the prevention of chronic conditions, this proposal aims to determine how antecedent metabolic health affects the response to metformin treatment, and identify the relationship between skeletal muscle mitochondrial remodeling and mitochondrial function with metformin treatment. The hypotheses are that: 1) metformin treatment in subjects free of Type 2 diabetes will improve insulin sensitivity and glucoregulation in insulin resistant individuals, but will decrease insulin sensitivity and glucoregulation in insulin sensitive subjects, and 2) long-term metformin treatment will remodel mitochondria in a way that decreases mitochondrial function in subjects that are insulin sensitive, but improves mitochondrial function in subjects that are insulin resistant. To test these hypotheses, a 12-week randomized, double-blind clinical trial will be performed in subjects 40-75 yrs of age, free of disease, and stratified by insulin sensitivity (insulin sensitive and insulin resistant). Pre- and post-training assessments include the hyperinsulinemic- euglycemic clamp to measure hepatic and peripheral insulin sensitivity, continuous glucose monitoring to determine glucoregulation, and proposed blood-based biomarkers of aging. Further, the use of novel stable isotope labeling with proteomic analysis will determine individual and complex-specific mitochondrial remodeling. This approach will be combined with analysis of protein modification and turnover to comprehensively analyze mitochondrial effects of metformin treatment in skeletal muscle. By completion of this project, it is expected that there will be evidence that helps further delineate who may benefit from metformin treatment to slow aging.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53705
- University of Wisconsin-Madison
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- 40-75 years of age (inclusive)
- Free of chronic disease
- Comprehension of the protocol as indicated by an ability to respond to questions about the study after reading the consent form.
- Able to use and be contacted by telephone.
- Able to speak, read, and understand English, and complete a questionnaire in English
- Independently mobile
Exclusion Criteria:
- Pregnancy
- Heart disease (history, abnormal ECG, abnormal stress ECG)
- Cerebrovascular disease (history)
- Cancer (history)
- Chronic respiratory disease (history, forced expiratory volume at one second/forced vital capacity [FEV1/FVC] < 70, FEV1 < 80% predicted)
- Chronic liver disease (history, alanine transaminase [ALT] > 52 IU/L)
- Diabetes (history, HbA1C ≥ 6.5, fasting blood glucose≥126 mg/dl, oral glucose tolerance test [OGTT] ≥ 200 mg/dl at 2 hrs)
- Impaired kidney function (eGFR ,45 mL/min)
- B12 lab values outside of normal range (<193 or >982 pg/mL)
- Alzheimer's (history)
- Chronic kidney disease (history, abnormal blood kidney panel including serum creatinine > 1.4)
- Problems with bleeding, on medication that prolongs bleeding time (if subject cannot safely stop prior to biopsy)
- Those on glucose lowering drugs
- Those planning to have imaging that requires intravenous contrast dye (within 6 weeks) or are on any of the following medications since they are contraindicated with the use of metformin: Dofetilide, Lamotrigine, Pegvisomant, Somatropin, Trimethoprim, Trospium, Gatifloxacin, Cephalexin, Cimetidine, Dalfampridine
- Tobacco use
- Allergies to lidocaine or metformin
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Metformin - Insulin Sensative
The investigators use a "ramp up" dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort. |
Metformin (Hunter Pharmacy) following a "ramp up" dosing protocol with a targeted dose of 1500 mg/day for 12 weeks.
Ostatní jména:
|
|
Komparátor placeba: Placebo - Insulin Sensitive
Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate). The same dosing schedule will be followed as for metformin. The investigators use a "ramp up" dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort. |
Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
Ostatní jména:
|
|
Experimentální: Metformin - Insulin Resistant
The investigators use a "ramp up" dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort. |
Metformin (Hunter Pharmacy) following a "ramp up" dosing protocol with a targeted dose of 1500 mg/day for 12 weeks.
Ostatní jména:
|
|
Komparátor placeba: Placebo - Insulin Resistant
Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate). The same dosing schedule will be followed as for metformin. The investigators use a "ramp up" dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort. |
Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean Change in Insulin Sensitivity Index
Časové okno: Change from baseline to 12 weeks
|
Insulin Sensitivity Index = M / I x 1000. M = Glucose disposal rate (mg/min), normalized to fat-free mass (kg). I = insulin concentration (mU/L) during steady state of the clamp (based on glucose infusion rate). We rely on the delta (post-pre) of the insulin sensitivity index as our primary outcome. Positive delta values indicate improved insulin sensitivity (a positive outcome), while negative delta values indicate lower insulin sensitivity (a negative outcome). Insulin sensitivity cannot be physiologically zero or negative. Maximum negative change insulin sensitivity index = -52.31 mg/kg FFM/min/mU/L. Maximum positive insulin sensitivity index = 42.32 mg/kg FFM/min/mU/L. |
Change from baseline to 12 weeks
|
|
Mean Change in Mitochondrial Function of the Electron Transport System Measured by Complex I Activity
Časové okno: Change from baseline to 12 weeks
|
Mitochondrial respiration was measured using permeabilized muscle fibers from the vastus lateralis using high-resolution respirometry. We rely on the delta (change from post-pre) of the Complex I mitochondrial respiratory capacity. Positive values indicate an increase in mitochondrial respiratory capacity and improved outcomes, while negative values indicate a reduction in mitochondrial respiratory capacity and a negative outcome. There is no minimum or maximum reported for mitochondrial respiratory capacity of CI, but mitochondrial respiratory capacity of CI cannot physiologically be zero or negative. We and others have previously reported maximal complex I linked oxidative phosphorylation at approximately 250 pmol/mg of tissue/s in ultra-endurance athletes. |
Change from baseline to 12 weeks
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean Change in Daily Average Glucose Measure
Časové okno: Change from baseline to 12 weeks
|
We measured blood glucose using a Dexcom Continuous Glucose Monitor (CGM) over seven days. We rely on the delta (change from pre to post) in mean glucose (mg/dL) levels. Positive values indicate an increase in blood glucose and a negative outcome, while negative values indicate a reduction in mean blood glucose and a positive outcome. Glucose values of 70-140 mg/dL generally represent a normal physiological range; values below 70 mg/dL indicate hypoglycemia excursions, while values above 180 mg/dL indicate hyperglycemia excursions. |
Change from baseline to 12 weeks
|
|
Mean Change in Blood-based Biomarker Measures of Aging
Časové okno: Change from baseline to 12 weeks
|
This blood-based biomarker panel, developed by LeBrasseur and colleagues, measures changes in senescence-associated secretory phenotype proteins. This panel is associated with chronological age, biological age, and adverse clinical outcomes. Changes in the protein levels of biomarkers reflect changes in biological age. A greater abundance in these biomarkers is associated with greater frailty or biological aging. We rely on the delta (change from post-pre) of the biological markers. A positive value is associated with a negative outcome, while a negative value is associated with a positive outcome. |
Change from baseline to 12 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Benjamin F Miller, PhD, Oklahoma Medical Research Foundation
- Vrchní vyšetřovatel: Adam Konopka, PhD, University of Wisconsin, Madison
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 10699
- R01AG064951 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Results from the trial will be disseminated through presentations at professional meetings and through peer-reviewed publications. Data and other resources will be shared as required by NIH Resource Sharing policies.
Časový rámec sdílení IPD
De-identified data will be shared following the publication of the primary manuscripts for each specific aim from the trial by the trial investigators.
Kritéria přístupu pro sdílení IPD
Researchers interested in accessing de-identified data will contact the trial principal investigators to complete data use agreements and paper/presentation proposals needed for consideration of the proposed research.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- ANALYTIC_CODE
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .